ERBB2 and breast carcinoma: HER2 protein expression is most commonly detected via semi-quantitative IHC analysis on paraffin embedded tissues using established protocols employed for the assessment of breast cancer patients being considered for anti-HER2 Herceptin (trastuzumab) treatment [9].